These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38917944)

  • 1. Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.
    Guerini-Rocco E; Venetis K; Cursano G; Mane E; Frascarelli C; Pepe F; Negrelli M; Olmeda E; Vacirca D; Ranghiero A; Trapani D; Criscitiello C; Curigliano G; Rolfo C; Malapelle U; Fusco N
    Crit Rev Oncol Hematol; 2024 Sep; 201():104427. PubMed ID: 38917944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
    Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
    Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
    Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
    Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
    Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
    Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
    Bhave MA; Quintanilha JCF; Tukachinsky H; Li G; Scott T; Ross JS; Pasquina L; Huang RSP; McArthur H; Levy MA; Graf RP; Kalinsky K
    Breast Cancer Res Treat; 2024 Oct; 207(3):599-609. PubMed ID: 38872062
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

  • 9. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
    Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
    EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
    Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F
    Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
    Gerratana L; Davis AA; Velimirovic M; Clifton K; Hensing WL; Shah AN; Dai CS; Reduzzi C; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Puglisi F; Ma CX; Bardia A; Cristofanilli M
    Breast Cancer Res; 2023 Oct; 25(1):112. PubMed ID: 37784176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
    Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
    Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
    Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
    Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
    JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
    Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
    Breast Cancer Res; 2024 Apr; 26(1):69. PubMed ID: 38650031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
    Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
    Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
    Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Fribbens C; Garcia Murillas I; Beaney M; Hrebien S; O'Leary B; Kilburn L; Howarth K; Epstein M; Green E; Rosenfeld N; Ring A; Johnston S; Turner N
    Ann Oncol; 2018 Jan; 29(1):145-153. PubMed ID: 29045530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
    Bardia A; Mayer I; Winer E; Linden HM; Ma CX; Parker BA; Bellet M; Arteaga CL; Cheeti S; Gates M; Chang CW; Fredrickson J; Spoerke JM; Moore HM; Giltnane J; Friedman LS; Chow Maneval E; Chan I; Jhaveri K
    Breast Cancer Res Treat; 2023 Jan; 197(2):319-331. PubMed ID: 36401732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.